Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

KROS

Keros Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1664710Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$244.0M
Net Income FY2025
$87.0M
EPS (Basic, as reported)
$2.34
Net Margin FY2025
35.7%
ROE FY2025
28.7%
Total Equity
$303.0M
Shares Out
20M
Business description

Keros Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 10 → 244 +70.3% CAGR
Fiscal yearFY2019FY2020⚑FY2021FY2022FY2023FY2024FY2025
Revenue10020004244
Research & development(17)(34)(55)(87)(135)(174)(130)
General & administrative(3)(13)(21)(28)(35)(41)(47)
Total operating expenses(21)(47)(76)(115)(170)(214)(176)
Operating income(11)(47)(56)(115)(170)(211)68
Interest expense—00000—
Other income (expense), net(2)1010172424
Pre-tax income(12)(46)(57)(105)(153)(187)92
Income tax expense00(2)000(5)
Net income(12)(45)(59)(105)(153)(187)87
EPS — basic—($2.93)($2.52)($4.15)($5.20)($5.00)$2.34
EPS — diluted—($2.93)($2.52)($4.15)($5.20)($5.00)$2.30
Shares outstanding — basic (M)—162325293737
Shares outstanding — diluted (M)—162325293738
  • ⚑ Weighted-average shares changed ×1.44 between FY2020 and FY2021 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.